Anti-CD154 monoclonal antibody promotes donor-specific tolerance
| Group . | Average time to rejection of skin grafts (d) . | |
|---|---|---|
| BALB/c . | C3H/HeN . | |
| B6 nontransplantation controls | 19.8 ± 1.9* | 17.2 ± 3.5 |
| hIgG-treated rejected mice | 15.8 ± 2.3 | 15.8 ± 2.3 |
| Anti-CD154–treated chimeric mice | Accept > 6 mo† | 15.4 ± 2.6 |
| Group . | Average time to rejection of skin grafts (d) . | |
|---|---|---|
| BALB/c . | C3H/HeN . | |
| B6 nontransplantation controls | 19.8 ± 1.9* | 17.2 ± 3.5 |
| hIgG-treated rejected mice | 15.8 ± 2.3 | 15.8 ± 2.3 |
| Anti-CD154–treated chimeric mice | Accept > 6 mo† | 15.4 ± 2.6 |
B6 mice were irradiated with 200 cGy TBI on day −1 and infused with 40 × 106 BALB/c BM on day 0. Irrelevant hamster IgG or anti-CD154 mAb was administered from day −1 through day 14 after BMT. PBLs were typed for percentage donor-host at 6 weeks after BMT. Five months after BMT, donor-type (BALB/c) or third-party (C3H/HeN) skin grafts were placed on B6 nontransplantation control mice, hIgG-treated rejected mice, and anti-CD154–treated chimeric mice (n = 5 per group). Shown is average time to rejection of grafts in days ± 1 SD. Anti-CD154–treated chimeric mice maintained their BALB/c skin grafts for more than 6 months.
hIgG indicates hamster immunoglobulin G; TBI, total body irradiation; BMT, bone marrow transplantation; mAb, monoclonal antibody; PBL, peripheral blood leukocyte.
P = .017
P < .001 compared with hIgG-treated rejected mice.